Stereotaxis, Inc. (STXS)

Market Cap	183.86M
Revenue (ttm)	25.14M
Net Income (ttm)	-22.89M
Shares Out	84.73M
EPS (ttm)	-0.27
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	156,849
Open	2.130
Previous Close	2.080
Day's Range	2.110 - 2.210
52-Week Range	1.660 - 3.290
Beta	1.54
Analysts	Strong Buy
Price Target	4.50 (+107.37%)
Earnings Date	Mar 3, 2025

About STXS

Stereotaxis, Inc. designs, manufactures, and markets robotic systems, instruments, and information systems for the interventional laboratory in the United States and internationally. Its robotic magnetic navigation (RMN) systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company provides Odyssey, a real-time information solution to manage,...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• IPO Date: Aug 12, 2004
• Employees: 122
• Stock Exchange: NYSEAMERICAN
• Ticker Symbol: STXS
• Website: https://www.stereotaxis.com

Financial Performance

In 2023, Stereotaxis's revenue was $26.77 million, a decrease of -4.89% compared to the previous year's $28.15 million. Losses were -$22.06 million, 12.3% more than in 2022.

Analyst Forecast

According to 2 analysts, the average rating for STXS stock is "Strong Buy." The 12-month stock price forecast is $4.5, which is an increase of 107.37% from the latest price.

Price Target

$4.5

(107.37% upside)

Analyst Consensus: Strong Buy